Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas
Authors' conclusion
This meta-analysis suggests that patients with metastatic PPGLs can benefit from TKI therapy with PR and DCR up to more than 30% and 80%. However, because of restricted studies, larger clinical trials should be performed in the future.
Study context
- Population
- Patients with metastatic PPGLs
- Participants
- 160 patients7 studies
- Outcome
- Tumor response or survival data and incidence of AEs after treatment
Methodological detailsfixed- or random-effect models, weighted median of medians method, Searched PubMed, Cochrane Library, Scopus, Clinical Trial and Embase to August 2022; risk of bias by MIONRS scale and JBI tools
- Fixed- or random-effect models
- Weighted median of medians method
- Searched PubMed, Cochrane Library, Scopus, Clinical Trial and Embase to August 2022; risk of bias by MIONRS scale and JBI tools
Pooled result
As reported in the abstract
Tumour response (pooled proportions; 5 studies)
Pooled proportion of partial response (PR)
0.320
95% CI 0.155–0.486
Pooled proportion of stable disease
0.520
95% CI 0.409–0.630
Pooled disease control rate (DCR)
0.856
95% CI 0.734–0.979
Further pooled results
Progression-free survival (combined median; 6 studies)
- Combined median progressive-free survival
- 8.9 months (95% CI 4.1-13.5)
Safety
Discontinuation due to adverse events (AEs) (5 studies)
- Proportion discontinued due to AEs
- 0.143 (95% CI 0.077-0.209)
Original publication
Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas. J Clin Endocrinol Metab. Published 16 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →